<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RAYOS- prednisone tablet, delayed release </strong><br>Horizon Pharma Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use RAYOS safely and effectively. See full prescribing information for RAYOS.<br><br> RAYOS (prednisone) delayed-release tablets 1 mg, 2 mg, 5 mg<br> Initial U.S. Approval: [1955]</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">RAYOS is a corticosteroid indicated </p>
<ul class="Disc">
<li>as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation (<a href="#S1">1</a>)</li>
<li>for the treatment of certain endocrine conditions (<a href="#S1">1</a>)</li>
<li>for palliation of certain neoplastic conditions (<a href="#S1">1</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Individualize dosing based on disease severity and patient response. The timing of administration should take into account the delayed-release pharmacokinetics and the disease or condition being treated (<a href="#S2">2</a>,<a href="#S12.1"> 12.1</a>): </p>
<ul class="Disc">
<li>Initial dose: RAYOS 5 mg administered once per day. Patients currently on immediate-release prednisone, prednisolone, or methylprednisolone should be switched to RAYOS at an equivalent dose based on relative potency. (<a href="#S2.1">2.1</a>,<a href="#S2.4"> 2.4</a>)</li>
<li>Maintenance dose: Use lowest dosage that will maintain an adequate clinical response. (<a href="#S2.1">2.1</a>)</li>
<li>Discontinuation: Withdraw gradually if discontinuing long-term or high-dose therapy. (<a href="#S2.1">2.1</a>)</li>
<li>RAYOS should be taken daily with food. (<a href="#S2.3">2.3</a>,<a href="#S12.3"> 12.3</a>)</li>
<li>RAYOS should be swallowed whole and not broken, divided, or chewed. (<a href="#S2.3">2.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Delayed-release tablets: 1 mg, 2 mg, and 5 mg prednisone (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to prednisone or any excipients in the formulation (<a href="#S4">4</a>,<a href="#S6"> 6</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>: Monitor patients for these conditions with chronic use. Taper doses gradually for withdrawal after chronic use. (<a href="#S5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Increased susceptibility to new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and increased risk of exacerbation, dissemination, or reactivation of latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be masked. (<a href="#S5.2">5.2</a>)</li>
<li>Elevated blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>: Monitor blood pressure and sodium, potassium serum levels (<a href="#S5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">GI perforation</span>: increased risk in patients with certain GI disorders. Signs and symptoms may be masked. (<a href="#S5.4">5.4</a>)</li>
<li>Behavioral and mood disturbances: May include <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. Existing conditions may be aggravated. (<a href="#S5.5">5.5</a>)</li>
<li>Decreases in bone density: Monitor bone density in patients receiving long term corticosteroid therapy. (<a href="#S5.6">5.6</a>)</li>
<li>Ophthalmic effects: May include <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Monitor intraocular pressure if corticosteroid therapy is continued for more than 6 weeks (<a href="#S5.7">5.7</a>)</li>
<li>Live or live attenuated vaccines: Do not administer to patients receiving immunosuppressive doses of corticosteroids. (<a href="#S5.8">5.8</a>)</li>
<li>Negative effects on growth and development: Monitor pediatric patients on long-term corticosteroid therapy. (<a href="#S5.9">5.9</a>)</li>
<li>Use in pregnancy: Fetal harm can occur with first trimester use. Apprise women of potential harm to fetus. (<a href="#S5.10">5.10</a>,<a href="#S8.1"> 8.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse reactions for corticosteroids include <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, alteration in glucose tolerance, elevation in blood pressure, behavioral and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Horizon Pharma USA, Inc. at 1-866-479-6742 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<span class="Italics">.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Anticoagulant agents: May enhance or diminish anticoagulant effects. (<a href="#S7.4">7.4</a>)</li>
<li>Antidiabetic agents: May increase blood glucose concentrations. Dose adjustments of antidiabetic agents may be required. (<a href="#S7.5">7.5</a>)</li>
<li>CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (<a href="#S7.7">7.7</a>,<a href="#S7.8"> 7.8</a>)</li>
<li>Cyclosporine: Increase in activity of both, cyclosporine and corticosteroid when administered concurrently. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with concurrent use. (<a href="#S7.10">7.10</a>)</li>
<li>NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (<a href="#S7.13">7.13</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div><div></div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Allergic Conditions</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Dermatologic Diseases</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Endocrine Conditions</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Gastrointestinal Diseases</a></h2>
<h2><a href="#section-1.5" class="toc">1.5 Hematologic Diseases</a></h2>
<h2><a href="#section-1.6" class="toc">1.6 Neoplastic Conditions</a></h2>
<h2><a href="#section-1.7" class="toc">1.7 Nervous System Conditions</a></h2>
<h2><a href="#section-1.8" class="toc">1.8 Ophthalmic Conditions</a></h2>
<h2><a href="#section-1.9" class="toc">1.9 Conditions Related to Organ Transplantation</a></h2>
<h2><a href="#section-1.10" class="toc">1.10 Pulmonary Diseases</a></h2>
<h2><a href="#section-1.11" class="toc">1.11 Renal Conditions</a></h2>
<h2><a href="#section-1.12" class="toc">1.12 Rheumatologic Conditions</a></h2>
<h2><a href="#section-1.13" class="toc">1.13 Specific Infectious Diseases</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Monitoring</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Method of Administration</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Corticosteroid Comparison Chart</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Alterations in Endocrine Function</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Increased Risks Related to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Alterations in Cardiovascular/Renal Function</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use in Patients with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Behavioral and Mood Disturbances</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Decrease in Bone Density</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Ophthalmic Effects</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Vaccination</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Effect on Growth and Development</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Use in Pregnancy</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Neuromuscular Effects</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Aminoglutehimide</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Amphotericin B Injection</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Anticholinesterase Agents</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Anticoagulant Agents</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Antidiabetic Agents</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Antitubercular Drugs</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin)</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics)</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Cholestyramine</a></h2>
<h2><a href="#section-7.10" class="toc">7.10 Cyclosporine</a></h2>
<h2><a href="#section-7.11" class="toc">7.11 Digitalis</a></h2>
<h2><a href="#section-7.12" class="toc">7.12 Estrogens, Including Oral Contraceptives</a></h2>
<h2><a href="#section-7.13" class="toc">7.13 Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Including Aspirin and Salicylates</a></h2>
<h2><a href="#section-7.14" class="toc">7.14 Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B)</a></h2>
<h2><a href="#section-7.15" class="toc">7.15 Skin Tests</a></h2>
<h2><a href="#section-7.16" class="toc">7.16 Toxoids and Live or Attenuated Vaccines</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">RAYOS is indicated in the treatment of the following diseases or conditions:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Allergic Conditions</h2>
<p class="First">Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adults and pediatric populations with:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic dermatitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span> reactions</li>
<li>Seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Dermatologic Diseases</h2>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis</li>
<li><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span></li>
<li>Exfoliative <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">erythroderma</span></li>
<li><span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">Mycosis fungoides</span></li>
<li><span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">Pemphigus</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>)</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Endocrine Conditions</h2>
<ul class="Disc">
<li>Congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></li>
<li><span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of malignancy</span></li>
<li>Nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span></li>
<li>Primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span>: hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Gastrointestinal Diseases</h2>
<p class="First">During acute episodes in:</p>
<ul class="Disc">
<li>Crohn's Disease</li>
<li><span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative colitis</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.5"></a><a name="section-1.5"></a><p></p>
<h2>1.5 Hematologic Diseases</h2>
<ul class="Disc">
<li>Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span></li>
<li>Diamond-Blackfan <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></li>
<li><span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span> in adults</li>
<li>Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span></li>
<li>Secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in adults</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.6"></a><a name="section-1.6"></a><p></p>
<h2>1.6 Neoplastic Conditions</h2>
<p class="First">For the treatment of:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">Acute leukemia</span></li>
<li>Aggressive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.7"></a><a name="section-1.7"></a><p></p>
<h2>1.7 Nervous System Conditions</h2>
<ul class="Disc">
<li>Acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span></li>
<li><span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Cerebral edema</span> associated with primary or metastatic <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span>, craniotomy or <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.8"></a><a name="section-1.8"></a><p></p>
<h2>1.8 Ophthalmic Conditions</h2>
<ul class="Disc">
<li>Sympathetic ophthalmia</li>
<li><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> and ocular inflammatory conditions unresponsive to topical steroids</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.9"></a><a name="section-1.9"></a><p></p>
<h2>1.9 Conditions Related to Organ Transplantation</h2>
<ul class="Disc"><li>Acute or chronic solid organ rejection</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.10"></a><a name="section-1.10"></a><p></p>
<h2>1.10 Pulmonary Diseases</h2>
<ul class="Disc">
<li>Acute exacerbations of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>)</li>
<li>Allergic <span class="product-label-link" type="condition" conceptid="261053" conceptname="Pneumonia in aspergillosis">bronchopulmonary aspergillosis</span></li>
<li><span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></li>
<li>Fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate chemotherapy</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span></li>
<li>Idiopathic <span class="product-label-link" type="condition" conceptid="4222731" conceptname="Obliterative bronchiolitis">bronchiolitis obliterans</span> with <span class="product-label-link" type="condition" conceptid="4045260" conceptname="Bronchiolitis obliterans organizing pneumonia">organizing pneumonia</span></li>
<li>Idiopathic <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonias</span></li>
<li><span class="product-label-link" type="condition" conceptid="45763750" conceptname="Idiopathic pulmonary fibrosis">Idiopathic pulmonary fibrosis</span></li>
<li><span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis carinii pneumonia</span> (PCP) associated with <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span> occurring in an HIV(+) individual who is also under treatment with appropriate anti-PCP antibiotics.</li>
<li>Symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.11"></a><a name="section-1.11"></a><p></p>
<h2>1.11 Renal Conditions</h2>
<ul class="Disc"><li>To induce a <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, without <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, of the idiopathic type or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span></li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.12"></a><a name="section-1.12"></a><p></p>
<h2>1.12 Rheumatologic Conditions</h2>
<p class="First">As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:</p>
<ul class="Disc"><li>Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></li></ul>
<p>During an exacerbation or as maintenance therapy in selected cases of:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing spondylitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">Dermatomyositis</span>/<span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span></li>
<li><span class="product-label-link" type="condition" conceptid="255348" conceptname="Polymyalgia rheumatica">Polymyalgia rheumatica</span></li>
<li><span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">Psoriatic arthritis</span></li>
<li>Relapsing polychondritis</li>
<li><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may require low dose maintenance therapy)</li>
<li>Sjogren's syndrome</li>
<li><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span></li>
<li><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.13"></a><a name="section-1.13"></a><p></p>
<h2>1.13 Specific Infectious Diseases</h2>
<ul class="Disc">
<li>Trichinosis with neurologic or myocardial involvement.</li>
<li>Tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">Dosage of RAYOS should be individualized according to the severity of the disease and the response of the patient. For pediatric patients, the recommended dosage should be governed by the same considerations rather than strict adherence to the ratio indicated by age or body weight.</p>
<p>The maximal activity of the adrenal cortex is between 2 am and 8 am and is minimal between 4 pm and midnight. Exogenous corticosteroids suppress adrenocorticoid activity the least when given at the time of maximal activity. RAYOS is a delayed-release formulation of prednisone which releases the active substance beginning approximately 4 hours after intake [<span class="Italics">see<a href="#S12.3">  Clinical Pharmacokinetics(12.3)</a></span>]. The timing of RAYOS administration should take into account the delayed-release pharmacokinetics and the disease or condition being treated.</p>
<p>The initial dosage of RAYOS may vary from 5 to 60 mg per day depending on the specific disease entity being treated. Patients currently on immediate release prednisone, prednisolone, or methylprednisolone should be switched to RAYOS at an equivalent dose based on relative potency (2.4).</p>
<p>In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period there is a lack of satisfactory clinical response, RAYOS should be discontinued and the patient transferred to other appropriate therapy. It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient.</p>
<p>After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of RAYOS for a period of time consistent with the patient's condition. If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Monitoring</h2>
<p class="First">Blood pressure, body weight, routine laboratory studies (including 2-hour postprandial blood glucose and serum potassium), and chest X-ray should be obtained at regular intervals during prolonged therapy with RAYOS. Upper GI X-rays are desirable in patients with known or suspected <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Method of Administration</h2>
<p class="First">RAYOS is for oral administration.</p>
<p>RAYOS should be taken daily with food.<span class="Italics"> [see<a href="#S12.3"> Clinical Pharmacokinetics (12.3)</a>]</span></p>
<p>RAYOS tablets should not be broken, divided, or chewed because the delayed release of prednisone is dependent on an intact coating. (11)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Corticosteroid Comparison Chart</h2>
<p class="First">For the purpose of comparison, one 5 mg RAYOS tablet is the equivalent milligram dosage of the following various corticosteroids:</p>
<table width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Betamethasone, 0.75 mg</td>
<td class="Rrule" align="left">Paramethasone, 2 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cortisone, 25 mg</td>
<td class="Rrule" align="left">Prednisolone, 5 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Dexamethasone, 0.75 mg</td>
<td class="Rrule" align="left">Prednisone, 5 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hydrocortisone, 20 mg</td>
<td class="Rrule" align="left">Triamcinolone, 4 mg</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Methylprednisolone, 4 mg</td>
<td class="Rrule" align="left"></td>
</tr>
</tbody>
</table>
<p>These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Delayed-release Tablets</p>
<ul class="Disc">
<li>RAYOS 1 mg prednisone: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> yellowish-white, round, unscored delayed-release tablet embossed with "NP 1" on one side.</li>
<li>RAYOS 2 mg prednisone: Yellowish-white, round, unscored delayed-release tablet embossed with "NP 2" on one side.</li>
<li>RAYOS 5 mg prednisone: Light yellow, round, unscored delayed-release tablet embossed with "NP 5" on one side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">RAYOS is contraindicated in patients who have known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to prednisone or to any of the excipients. Rare instances of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have occurred in patients receiving corticosteroid therapy [<span class="Italics">see<a href="#S6"> Adverse Reactions (6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Alterations in Endocrine Function</h2>
<p class="First">Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. Monitor patients for these conditions with chronic use.</p>
<p>Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment. Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving corticosteroids already, dosage may have to be increased.</p>
<p>Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. Mineralocorticoid supplementation is of particular importance in infancy.</p>
<p>Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Increased Risks Related to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
<p class="First">Corticosteroids may increase the risks related to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with any pathogen, including viral, bacterial, fungal, protozoan, or <span class="product-label-link" type="condition" conceptid="194873" conceptname="Mixed intestinal helminthiasis">helminthic infections</span>. The degree to which the dose, route and duration of corticosteroid administration correlates with the specific risks of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not well characterized, however, with increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.</p>
<p>Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and may reduce resistance to new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p><span class="Italics">Corticosteroids may exacerbate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and increase risk of disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span></p>
<p>The use of prednisone in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for management of the disease in conjunction with an appropriate anti-tuberculous regimen.</p>
<p><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In children or adults who have not had these diseases, particular care should be taken to avoid exposure. If a patient is exposed to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If patient is exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. If <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> develops, treatment with antiviral agents may be considered.</p>
<p>Corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
<p>Corticosteroids may exacerbate systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and therefore should not be used in the presence of such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> unless they are needed to control drug reactions.</p>
<p><span class="Italics">Corticosteroids may increase risk of reactivation or exacerbation of latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
<p>Corticosteroids may activate latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>. Therefore, it is recommended that latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Corticosteroids should not be used in <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Alterations in Cardiovascular/Renal Function</h2>
<p class="First">Corticosteroids can cause elevation of blood pressure, salt, and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium and calcium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. These agents should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p>Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; therefore, therapy with corticosteroids should be used with great caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use in Patients with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></h2>
<p class="First">There is an increased risk of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> in patients with certain GI disorders. Signs of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">GI perforation</span>, such as peritoneal irritation may be masked in patients receiving corticosteroids.</p>
<p>Corticosteroids should be used with caution if there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, or other pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>; fresh intestinal anastomoses; and active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Behavioral and Mood Disturbances</h2>
<p class="First">Corticosteroids use may be associated with central nervous system effects ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Decrease in Bone Density</h2>
<p class="First">Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in children and adolescents and the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at any age. Special consideration should be given to patients at increased risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (i.e., postmenopausal women) before initiating corticosteroid therapy and bone density should be monitored in patients on long term corticosteroid therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Ophthalmic Effects</h2>
<p class="First">Prolonged use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to fungi or viruses.</p>
<p>The use of oral corticosteroids is not recommended in the treatment of <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and may lead to an increase in the risk of new episodes.</p>
<p>Intraocular pressure may become elevated in some individuals. If corticosteroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.</p>
<p>Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. Corticosteroids should not be used in active ocular herpes simplex.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Vaccination</h2>
<p class="First">Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered; however, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.</p>
<p>While on corticosteroid therapy, patients should not be vaccinated against <span class="product-label-link" type="condition" conceptid="134573" conceptname="Smallpox">smallpox</span>. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Effect on Growth and Development</h2>
<p class="First">Long-term use of corticosteroids can have negative effects on growth and development in children.</p>
<p>Growth and development of pediatric patients on prolonged corticosteroid therapy should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Use in Pregnancy</h2>
<p class="First">Prednisone can cause fetal harm when administered to a pregnant woman. Human and animal studies suggest that use of corticosteroids during the first trimester of pregnancy is associated with an increased risk of orofacial clefts, intrauterine growth restriction, and decreased birth weight. If this drug is used during pregnancy, or if the patient becomes pregnant while using this drug, the patient should be apprised of the potential hazard to the fetus [<span class="Italics">see<a href="#S8.1"> Use in Specific Populations (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Neuromuscular Effects</h2>
<p class="First">Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect.</p>
<p>An <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> is generalized, may involve ocular and respiratory muscles, and may result in <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>. Elevation of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span></h2>
<p class="First">Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Common adverse reactions for corticosteroids include <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, alteration in glucose tolerance, elevation in blood pressure, behavioral and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>: </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, cardiac enlargement, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">fat embolism</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> in premature infants, <span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span></p>
<p><span class="Bold">Dermatologic: </span><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, cutaneous and subcutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry scalp</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, hyper or hypopigmentation, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold">Endocrine: </span>Abnormal fat deposits, decreased carbohydrate tolerance, development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> state, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus and increased requirements for insulin or oral hypoglycemic agents in diabetics, menstrual irregularities, moon facies, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery or illness), suppression of growth in children</p>
<p><span class="Bold">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span>: </span><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>, potassium loss, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span></p>
<p><span class="Bold">Gastrointestinal: </span>Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, elevation in serum liver enzymes levels (usually reversible upon discontinuation), <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span></p>
<p><span class="Bold">General: </span><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></p>
<p><span class="Bold">Metabolic: </span>Negative nitrogen balance due to protein catabolism</p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of femoral and humeral heads, charcot-like <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones, <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span></p>
<p><span class="Bold">Neurological: </span><span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (pseudo-tumor cerebri) usually following discontinuation of treatment, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4081615" conceptname="Paraparesis">paraparesis</span>/<span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold">Ophthalmic: </span><span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, and central serous <span class="product-label-link" type="condition" conceptid="4116208" conceptname="Choroidal and/or chorioretinal disorder">chorioretinopathy</span></p>
<p><span class="Bold">Reproductive: </span>Alteration in motility and number of spermatozoa</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of RAYOS was evaluated in 375 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients in two controlled trials. Patients treated with RAYOS ranged in age from 20 to 80 years (median age 56 years), with 85% female, 99% Caucasian, 1% African-American, and &lt;1% Asian.</p>
<p>Patients received RAYOS 3 mg to 10 mg once daily at 10 pm; the majority (84%) received ≤5 mg. The clinical trial experience did not raise new safety concerns beyond those already established for immediate-release prednisone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">Adverse reactions have been identified during post approval use of RAYOS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The postmarketing experience has not raised new safety concerns beyond those already established for immediate-release prednisone.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Aminoglutehimide</h2>
<p class="First">Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Amphotericin B Injection</h2>
<p class="First">There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span><span class="Italics"> [see<a href="#S7.14"> Drug Interactions (7.14)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Anticholinesterase Agents</h2>
<p class="First">Concomitant use of anticholinesterase agents and corticosteroids may produce severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Anticoagulant Agents</h2>
<p class="First">Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Antidiabetic Agents</h2>
<p class="First">Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Antitubercular Drugs</h2>
<p class="First">Serum concentrations of isoniazid may be decreased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7 CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin)</h2>
<p class="First">Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8 CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics)</h2>
<p class="First">Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.9"></a><a name="section-7.9"></a><p></p>
<h2>7.9 Cholestyramine</h2>
<p class="First">Cholestyramine may increase the clearance of corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.10"></a><a name="section-7.10"></a><p></p>
<h2>7.10 Cyclosporine</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Increased activity</span> of both cyclosporine and corticosteroids may occur when the two are used concurrently. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with this concurrent use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.11"></a><a name="section-7.11"></a><p></p>
<h2>7.11 Digitalis</h2>
<p class="First">Patients on digitalis glycosides may be at increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.12"></a><a name="section-7.12"></a><p></p>
<h2>7.12 Estrogens, Including Oral Contraceptives</h2>
<p class="First">Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.13"></a><a name="section-7.13"></a><p></p>
<h2>7.13 Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Including Aspirin and Salicylates</h2>
<p class="First">Concomitant use of aspirin or other nonsteroidal anti-inflammatory drugs and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. The clearance of salicylates may be increased with concurrent use of corticosteroids; this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.14"></a><a name="section-7.14"></a><p></p>
<h2>7.14 Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B)</h2>
<p class="First">When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.15"></a><a name="section-7.15"></a><p></p>
<h2>7.15 Skin Tests</h2>
<p class="First">Corticosteroids may suppress reactions to skin tests.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.16"></a><a name="section-7.16"></a><p></p>
<h2>7.16 Toxoids and Live or Attenuated Vaccines</h2>
<p class="First">Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible [<span class="Italics">see<a href="#S5.8"> Warnings and Precautions (5.8)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Teratogenic Effects</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First">Pregnancy Category D [see<a href="#S5.10"> Warnings and Precautions (5.10)</a>]: Multiple cohort and case controlled studies in humans suggest that maternal corticosteroid use during the first trimester increases the rate of <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span> with or without <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> from about 1/1000 infants to 3-5/1000 infants. Two prospective case control studies showed decreased birth weight in infants exposed to maternal corticosteroids in utero.</p>
<p>RAYOS was not formally evaluated for effects on reproduction. Published literature indicates prednisolone, the active metabolite of prednisone, has been shown to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in offspring. In <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> along with elevation of fetal lethality (or increase in resorptions) and reductions in fetal body weight were seen in rats at maternal doses of 30 mg/kg (equivalent to 290 mg in a 60 kg individual based on mg/m<span class="Sup">2</span> body surface comparison) and higher. <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">Cleft palate</span> was observed in mice at a maternal dose of 20 mg/kg (equivalent to 100 mg in a 60 kg individual based on mg/m<span class="Sup">2</span> comparison). Additionally, constriction of the ductus arteriosus has been observed in fetuses of pregnant rats exposed to prednisolone.</p>
<p>In humans, the risk of decreased birth weight appears to be dose related and may be minimized by administering lower corticosteroid doses. It is likely that underlying maternal conditions contribute to intrauterine growth restriction and decreased birth weight, but it is unclear to what extent these maternal conditions contribute to the increased risk of orofacial clefts.</p>
<p>Prednisolone can cause fetal harm when used in pregnancy. RAYOS should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If this drug is used during pregnancy, or if the patient becomes pregnant while using this drug, the patient should be apprised of the potential hazard to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Prednisolone, the active metabolite of prednisone, is secreted in human milk. Reports suggest that prednisolone concentrations in human milk are 5 to 25% of maternal serum levels, and that total infant daily doses are small, about 0.14% of the maternal daily dose. The risk of infant exposure to prednisolone through breast milk should be weighed against the known benefits of breastfeeding for both the mother and baby.</p>
<p>Caution should be exercised when RAYOS is administered to a nursing woman. If RAYOS must be prescribed to a breastfeeding mother, the lowest dose should be prescribed to achieve the desired clinical effect. High doses of corticosteroids for long periods could potentially produce problems in infant growth and development and interfere with endogenous corticosteroid production.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The efficacy and safety of prednisone in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> (&gt;2 years of age), and aggressive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> (&gt;1 month of age). However, some of these conclusions and other indications for pediatric use of corticosteroid, e.g., severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. The adverse effects of prednisone in pediatric patients are similar to those in adults [<span class="Italics">see<a href="#S6"> Adverse Reactions (6)</a></span>]. Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, psychosocial disturbances, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>.</p>
<p>Children who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in children than some commonly used tests of HPA axis function. The linear growth of children treated with corticosteroids by any route should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of other treatment alternatives. In order to minimize the potential growth effects of corticosteroids, children should be titrated to the lowest effective dose [<span class="Italics">see<a href="#S5.9"> Warnings and Precautions (5.9)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience with prednisone has not identified differences in responses between the elderly and younger patients. However, the incidence of corticosteroid-induced side effects may be increased in geriatric patients and are dose-related. <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> is the most frequently encountered complication, which occurs at a higher incidence rate in corticosteroid-treated geriatric patients as compared to younger populations and in age-matched controls. Losses of bone mineral density appear to be greatest early on in the course of treatment and may recover over time after steroid withdrawal or use of lower doses (i.e., ≤ 5 mg/day). Prednisone doses of 7.5 mg/day or higher have been associated with an increased relative risk of both vertebral and nonvertebral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, even in the presence of higher bone density compared to patients with involution <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. Routine screening of geriatric patients, including regular assessments of bone mineral density and institution of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> prevention strategies, along with regular review of prednisone indication should be undertaken to minimize complications and keep the prednisolone dose at the lowest acceptable level. Co-administration of certain bisphosphonates have been shown to retard the rate of bone loss in corticosteroid-treated males and postmenopausal females, and these agents are recommended in the prevention and treatment of corticosteroid-induced <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> [<span class="Italics">see<a href="#S5.6"> Warnings and Precautions (5.6)</a></span>].</p>
<p>It has been reported that equivalent weight-based doses yield higher total and unbound prednisolone plasma concentrations and reduced renal and non-renal clearance in elderly patients compared to younger populations. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The effects of accidental ingestion of large quantities of prednisone over a very short period of time have not been reported, but prolonged use of the drug can produce mental symptoms, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>, abnormal fat deposits, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, excessive appetite, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, dry scaly skin, thinning scalp hair, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, decreased resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, negative nitrogen balance with delayed bone and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorders</span>, accentuated <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, decreased glucose tolerance, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>. <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> and abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> have been observed in children.</p>
<p>Treatment of acute overdosage is by immediate gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> followed by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy the dosage of prednisone may be reduced only temporarily, or alternate day treatment may be introduced.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">The active ingredient in RAYOS is prednisone (a corticosteroid). Corticosteroids are adrenocortical steroids, both naturally occurring and synthetic. The molecular formula for prednisone is C<span class="Sub">21</span>H<span class="Sub">26</span>O<span class="Sub">5</span>. The chemical name for prednisone is 17,21-dihydroxypregna-1,4-diene-3,11,20-trione, and the structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=281ab967-7565-4bef-9c0c-a646589c671e&amp;name=rayos-01.jpg"></div>
<p>Prednisone is a white to practically white, odorless, crystalline powder and has a molecular weight of 358.43. Prednisone is very slightly soluble in water; slightly soluble in alcohol, chloroform, dioxane, and methanol.</p>
<p>RAYOS is a delayed-release prednisone tablet. It consists of a prednisone-containing core tablet in an inactive shell, which delays the onset of in vitro drug dissolution by approximately 4 hours. Each tablet contains 1 mg, 2 mg, or 5 mg of prednisone, with the following inactive ingredients: dibasic calcium phosphate dihydrate, colloidal silicon dioxide, croscarmellose sodium, glycerol dibehenate, lactose monohydrate, magnesium stearate, povidone, yellow ferric oxide, and red ferric oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Naturally occurring corticosteroids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, such as prednisone, are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.</p>
<p>Corticosteroids, such as prednisone, cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.</p>
<p>Prednisone is a synthetic adrenocortical steroid drug with predominantly corticosteroid properties. Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormones' normal functions; they are seen only after administration of large therapeutic doses of the drug. The pharmacological effects of prednisone which are due to its corticosteroid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion.</p>
<p>Depressed production of eosinophils and <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> occurs, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated. Inflammatory processes (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited.</p>
<p>Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetic profile of RAYOS has an approximately 4-hour lag time from that of immediate-release prednisone formulations. While the pharmacokinetic profile of RAYOS when given with food differs in terms of lag time from IR prednisone, its absorption, distribution, and elimination processes are comparable.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Prednisone is released from RAYOS when taken with food approximately 4 hours after oral ingestion. This causes a delay in the time until peak plasma concentrations (T<span class="Sub">max</span>) are achieved. Median T<span class="Sub">max</span> of RAYOS in 27 healthy male subjects was 6.0 - 6.5 hours compared to 2.0 hours for an immediate-release (IR) formulation. Subsequently, prednisone was absorbed at the same rate as the IR formulation. Peak plasma concentrations (C<span class="Sub">max</span>) and exposure, as indicated by AUC<span class="Sub">0-last</span> and AUC<span class="Sub">0-∞</span>, were comparable for both prednisone IR and RAYOS administered 2.5 hours after a light meal or with normal meal (Figure 1).</p>
<p><span class="Bold">Figure 1: Mean Plasma Levels of Prednisone After a Single Dose of 5 mg Prednisone Administered as a 5 mg RAYOS Tablet or a 5 mg Immediate-Release (IR) Tablet</span></p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=281ab967-7565-4bef-9c0c-a646589c671e&amp;name=rayos-02.jpg"></p>
<p>A: 5 mg IR tablet under fasting conditions, administered at 2 am, B: 5 mg RAYOS, administered 2.5 hours after a light evening meal, and C: 5 mg RAYOS administered immediately after dinner</p>
<p>In a study with 24 healthy subjects, oral absorption of prednisone from RAYOS was significantly affected by the intake of food. Under standard fasting conditions, both the maximum plasma concentration (C<span class="Sub">max</span>) and the bioavailability of RAYOS were significantly lower than under fed conditions, shortly after intake of a high fat meal.</p>
<p>RAYOS at dose levels of 1 mg, 2 mg, and 5 mg showed dose-proportionality in terms of peak and systemic exposure (C<span class="Sub">max</span>, AUC<span class="Sub">0-∞</span>, and AUC<span class="Sub">0-last</span>) for the parent drug prednisone as well as for the active metabolite prednisolone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>Prednisone is completely converted to the active metabolite prednisolone, which is further metabolized mainly in the liver and excreted in the urine as sulfate and glucuronide conjugates. The exposure of prednisolone is 4-6 fold higher than that of prednisone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Underline">Excretion</span></p>
<p>The terminal half-life of both prednisone and prednisolone from the administration of RAYOS was 2-3 hours, which is comparable to that from the IR formulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Underline">Special Populations</span></p>
<p>The effects of gender, age, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of prednisone or prednisolone after administration of RAYOS have not been evaluated.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Prednisone was not formally evaluated in carcinogenicity studies. Review of the published literature identified carcinogenicity studies of prednisolone, the active metabolite of prednisone, at doses which were less than the typical clinical doses. In a 2-year study, male Sprague-Dawley rats administered prednisolone in drinking water at a dose of 368 mcg/kg/day (equivalent to 3.5 mg/day in a 60-kg individual based on a mg/m<span class="Sup">2</span> body surface area comparison) developed increased incidences of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span>. Lower doses were not studied, and therefore, a no effect level could not be identified. In an 18-month study, intermittent oral gavage administration of prednisolone did not induce tumors in female Sprague-Dawley rats when given 1, 2, 4.5, or 9 times per month at 3 mg/kg prednisone (equivalent to 29 mg in a 60-kg individual based on a mg/m<span class="Sup">2</span> body surface area comparison).</p>
<p>Prednisone was not formally evaluated for genotoxicity. However, in published studies prednisolone was not mutagenic with or without metabolic activation in the Ames bacterial reverse mutation assay using<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium </span>and<span class="Italics"> Escherichia coli</span>, or in a mammalian cell gene mutation assay using mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> L5178Y cells, according to current evaluation standards. In a published chromosomal aberration study in Chinese Hamster Lung (CHL) cells, a slight increase was seen in the incidence of structural chromosomal aberrations with metabolic activation at the highest concentration tested, however, the effect appears to be equivocal. Prednisolone was not genotoxic in an<span class="Italics"> in vivo </span>micronucleaus assay in the mouse, though the study design did not meet current criteria.</p>
<p>Prednisone was not formally evaluated in fertility studies. However, menstrual irregularities have been described with clinical use [<span class="Italics">see<a href="#S6"> Adverse Reactions (6)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of RAYOS in the treatment of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> was assessed in one multicenter, double-blind, placebo-controlled, randomized, 12-week trial in patients ≥18 years with active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> diagnosed according to American College of Rheumatology (ACR) criteria. Patients were enrolled who were not currently treated with corticosteroids but had received non-biologic DMARD therapy for at least 6 months before receipt of study medication, and had an incomplete response to DMARD therapy alone. Patients were randomized in a 2:1 ratio to treatment with RAYOS 5 mg (n=231) or placebo (n=119) administered at 10 pm. A total of 350 patients were enrolled and ranged in age from 27 to 80 years (median age 57 years) with 84% females. Race was distributed as follows: 98% Caucasian, 1% African-American, and &lt;1% Asian.</p>
<p>The percentage of patients with improvement in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> at 12 weeks using ACR response criteria (ACR20) was assessed as the primary endpoint, and ACR20, ACR50 and ACR70 responses for patients treated with RAYOS 5 mg versus placebo are shown in Table 1. The relative efficacy of RAYOS compared to immediate-release prednisone has not been established.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: ACR Responses (Percentage of Patients)</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">ACR Response at 12 Weeks</th>
<th class="Rrule" align="center">RAYOS 5 mg</th>
<th class="Rrule" align="center">Placebo</th>
<th class="Rrule" align="center">RAYOS 5 mg – Placebo (95% CI)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">N=231</th>
<th class="Rrule" align="center">N=119</th>
<th class="Rrule" align="center"></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="4">All missing values were imputed as non-responders.</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">ACR20</td>
<td class="Rrule" align="center">47%</td>
<td class="Rrule" align="center">29%</td>
<td class="Rrule" align="center">17%<br>(7.2, 27.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ACR50</td>
<td class="Rrule" align="center">22%</td>
<td class="Rrule" align="center">10%</td>
<td class="Rrule" align="center">12%<br>(4.4, 19.6)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">ACR70</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%<br>(0.1, 8.7)</td>
</tr>
</tbody>
</table>
<p>The results of the components of the ACR response criteria are shown in Table 2.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2: Components of ACR Response</span></caption>
<col align="left" valign="top" width="32%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2" valign="middle">Parameter</th>
<th class="Rrule" align="center" colspan="2">RAYOS 5 mg + DMARD<br>N=231</th>
<th class="Rrule" align="center" colspan="2">Placebo + DMARD<br>N=119</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Baseline</th>
<th class="Rrule" align="center">Week 12</th>
<th class="Rrule" align="center">Baseline</th>
<th class="Rrule" align="center">Week 12</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">Mean (SD) is presented. Baseline values were carried forward for patients with missing data at Week 12.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>28-joint count</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Patient assessment of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Visual analog scale: 0 = no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, 100 = very intensive <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Patient or physician global assessment of disease activity. Visual analog scale: 0 = not active at all, 100 = extremely active</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Health Assessment Questionnaire <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Index; 0=best, 3=worst, measures the patient's ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Tender joint count<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">12.6 (6.2)</td>
<td class="Rrule" align="center">7.9 (6.8)</td>
<td class="Rrule" align="center">12.5 (5.9)</td>
<td class="Rrule" align="center">9.8 (6.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">Swollen joint</span> count<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">8.4 (4.4)</td>
<td class="Rrule" align="center">4.8 (4.8)</td>
<td class="Rrule" align="center">8.6 (4.7)</td>
<td class="Rrule" align="center">6.1 (5.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Patient assessment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">55.3 (21.9)</td>
<td class="Rrule" align="center">33.0 (24.5)</td>
<td class="Rrule" align="center">50.5 (23.3)</td>
<td class="Rrule" align="center">39.6 (24.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Patient global assessment<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">57.4 (20.1)</td>
<td class="Rrule" align="center">36.2 (24.5)</td>
<td class="Rrule" align="center">50.9 (20.9)</td>
<td class="Rrule" align="center">43.0 (22.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Physician global assessment<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">55.2 (16.1)</td>
<td class="Rrule" align="center">31.9 (19.7)</td>
<td class="Rrule" align="center">54.1 (17.4)</td>
<td class="Rrule" align="center">40.4 (21.8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> index (HAQ-DI)<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center">1.3 (0.6)</td>
<td class="Rrule" align="center">1.1 (0.6)</td>
<td class="Rrule" align="center">1.3 (0.6)</td>
<td class="Rrule" align="center">1.2 (0.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ESR (mm/hr)</td>
<td class="Rrule" align="center">33.0 (16.6)</td>
<td class="Rrule" align="center">25.2 (16.8)</td>
<td class="Rrule" align="center">32.9 (20.0)</td>
<td class="Rrule" align="center">26.5 (19.7)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">CRP (mg/dL)</td>
<td class="Rrule" align="center">9.3 (13.2)</td>
<td class="Rrule" align="center">7.5 (10.7)</td>
<td class="Rrule" align="center">11.8(18.0)</td>
<td class="Rrule" align="center">9.7 (12.1)</td>
</tr>
</tbody>
</table>
<p>The percentage of patients achieving ACR20 responses by visit is shown in Figure 2.</p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="100%">
<thead><tr><th align="left">Figure 2: ACR20 Response Over 12 Weeks<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</th></tr></thead>
<tfoot><tr><td colspan="1" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>The same patients may not have responded at each time point.</dd>
</dl></td></tr></tfoot>
<tbody><tr><td align="left"><p class="First"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=281ab967-7565-4bef-9c0c-a646589c671e&amp;name=rayos-03.jpg"></p></td></tr></tbody>
</table>
<p>The percent change from baseline in the duration of morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> at 12 weeks was assessed as a prespecified secondary endpoint. Patients treated with RAYOS had a median decrease in the duration of morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> of 55% compared to 33% in placebo-treated patients (20% estimated median difference between treatment groups with 95% confidence interval [7, 32]). This corresponds to a median duration of morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> of 46 minutes in the RAYOS group and 85 minutes in the placebo group.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">RAYOS delayed-release tablets (1 mg prednisone) are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellowish-white, round, unscored tablets embossed with "NP 1" on one side and supplied as:</p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr>
<th align="left"><span class="Underline">NDC Number</span></th>
<th align="left"><span class="Underline">Size</span></th>
</tr></thead>
<tbody>
<tr>
<td align="left">75987-020-01</td>
<td align="left">Bottle of 30 tablets</td>
</tr>
<tr>
<td align="left">75987-020-02</td>
<td align="left">Bottle of 100 tablets</td>
</tr>
</tbody>
</table>
<p>RAYOS delayed-release tablets (2 mg prednisone) are yellowish-white, round, unscored tablets embossed with "NP 2" on one side and supplied as:</p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr>
<th align="left"><span class="Underline">NDC Number</span></th>
<th align="left"><span class="Underline">Size</span></th>
</tr></thead>
<tbody>
<tr>
<td align="left">75987-021-01</td>
<td align="left">Bottle of 30 tablets</td>
</tr>
<tr>
<td align="left">75987-021-02</td>
<td align="left">Bottle of 100 tablets</td>
</tr>
</tbody>
</table>
<p>RAYOS delayed-release tablets (5 mg prednisone) are light yellow, round, unscored tablets embossed with "NP 5" on one side and supplied as:</p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr>
<th align="left"><span class="Underline">NDC Number</span></th>
<th align="left"><span class="Underline">Size</span></th>
</tr></thead>
<tbody>
<tr>
<td align="left">75987-022-01</td>
<td align="left">Bottle of 30 tablets</td>
</tr>
<tr>
<td align="left">75987-022-02</td>
<td align="left">Bottle of 100 tablets</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature].</p>
<p>Protect RAYOS tablets from light and moisture.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be informed of the following information before initiating therapy with RAYOS and periodically during the course of ongoing therapy.</p>
<ul class="Disc">
<li>Patients should be warned not to discontinue the use of RAYOS abruptly or without medical supervision, to advise any medical attendants that they are taking it, and to seek medical advice at once should they develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients should be told to take RAYOS exactly as prescribed, follow the instructions on the prescription label, and not stop taking RAYOS without first checking with their healthcare providers, as there may be a need for gradual dose reduction.</li>
<li>Patients should discuss with their physician if they have had recent or ongoing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or if they have recently received a vaccine.</li>
<li>Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</li>
<li>There are a number of medicines that can interact with RAYOS. Patients should inform their healthcare provider of all the medicines they are taking, including over-the-counter and prescription medicines (such as phenytoin, diuretics, digitalis or digoxin, rifampin, amphotericin B, cyclosporine, insulin or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines, ketoconazole, estrogens including birth control pills and hormone replacement therapy, blood thinners such as warfarin, aspirin or other NSAIDS, barbiturates), dietary supplements, and herbal products. If patients are taking any of these drugs, alternate therapy, dosage adjustment, and/or special test may be needed during the treatment.</li>
<li>For missed doses, patients should be told to take the missed dose as soon as they remember. If it is almost time for the next dose, the missed dose should be skipped and the medicine taken at the next regularly schedule time. Patients should not take an extra dose to make up for the missed dose.</li>
<li>Patients should be told to take RAYOS with food. Patients should be advised not to break, divide, or chew RAYOS.</li>
<li>Patients should be advised of common adverse reactions that could occur with RAYOS use to include <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, alteration in glucose tolerance, elevation in blood pressure, behavioral and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Distributed by:<br>Horizon Pharma USA, Inc.<br>520 Lake Cook Road, Suite 520<br>Deerfield, IL 60015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1 mg Tablet Carton</span></p>
<p><span class="Bold">RAYOS<span class="Sup">®</span><br>(Prednisone) Delayed-release Tablets</span></p>
<p><span class="Bold">1 mg</span></p>
<p>100 Tablets</p>
<p>Rx Only</p>
<p><span class="Bold">ATTENTION PHARMACIST: </span>Dispense<br>attached medication guide to each patient.</p>
<p>Swallow whole. Do not crush, divide, or chew tablets.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 mg Tablet Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=281ab967-7565-4bef-9c0c-a646589c671e&amp;name=rayos-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 2 mg Tablet Carton</span></p>
<p><span class="Bold">RAYOS<span class="Sup">®</span><br>(Prednisone) Delayed-release Tablets</span></p>
<p><span class="Bold">2 mg</span></p>
<p>100 Tablets</p>
<p>Rx Only</p>
<p><span class="Bold">ATTENTION PHARMACIST: </span>Dispense<br>attached medication guide to each patient.</p>
<p>Swallow whole. Do not crush, divide, or chew tablets.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2 mg Tablet Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=281ab967-7565-4bef-9c0c-a646589c671e&amp;name=rayos-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg Tablet Carton</span></p>
<p><span class="Bold">RAYOS<span class="Sup">®</span><br>(Prednisone) Delayed-release Tablets</span></p>
<p><span class="Bold">5 mg</span></p>
<p>100 Tablets</p>
<p>Rx Only</p>
<p><span class="Bold">ATTENTION PHARMACIST: </span>Dispense<br>attached medication guide to each patient.</p>
<p>Swallow whole. Do not crush, divide, or chew tablets.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg Tablet Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=281ab967-7565-4bef-9c0c-a646589c671e&amp;name=rayos-06.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RAYOS 		
					</strong><br><span class="contentTableReg">prednisone tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:75987-020</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>prednisone</strong> (prednisone) </td>
<td class="formItem">prednisone</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Povidones</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Croscarmellose Sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Silicon Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Ferric Oxide Red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Ferric Oxide Yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Calcium Phosphate, Dibasic, Dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glyceryl Dibehenate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> Yellowish White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NP;1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:75987-020-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:75987-020-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:75987-020-70</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202020</td>
<td class="formItem">07/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RAYOS 		
					</strong><br><span class="contentTableReg">prednisone tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:75987-021</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>prednisone</strong> (prednisone) </td>
<td class="formItem">prednisone</td>
<td class="formItem">2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Povidones</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Croscarmellose Sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Silicon Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Ferric Oxide Red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Ferric Oxide Yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Calcium Phosphate, Dibasic, Dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glyceryl Dibehenate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> Yellowish White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NP;1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:75987-021-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:75987-021-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:75987-021-70</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202020</td>
<td class="formItem">07/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RAYOS 		
					</strong><br><span class="contentTableReg">prednisone tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:75987-022</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>prednisone</strong> (prednisone) </td>
<td class="formItem">prednisone</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Povidones</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Croscarmellose Sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Silicon Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Ferric Oxide Red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Ferric Oxide Yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Calcium Phosphate, Dibasic, Dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glyceryl Dibehenate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> Yellowish White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NP;1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:75987-022-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:75987-022-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:75987-022-70</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202020</td>
<td class="formItem">07/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Horizon Pharma Inc.
							(964613413)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bayer  Pharma AG</td>
<td class="formItem"></td>
<td class="formItem">341081414</td>
<td class="formItem">MANUFACTURE(75987-020, 75987-021, 75987-022)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PHAST GmbH</td>
<td class="formItem"></td>
<td class="formItem">331156161</td>
<td class="formItem">ANALYSIS(75987-020, 75987-021, 75987-022)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aenova France SAS</td>
<td class="formItem"></td>
<td class="formItem">263354778</td>
<td class="formItem">MANUFACTURE(75987-020, 75987-021, 75987-022)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Temmler Werke GmbH</td>
<td class="formItem"></td>
<td class="formItem">551195014</td>
<td class="formItem">PACK(75987-020, 75987-021, 75987-022), LABEL(75987-020, 75987-021, 75987-022)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Tianjin Tianyao Pharmaceuticals Co., Ltd</td>
<td class="formItem"></td>
<td class="formItem">654534197</td>
<td class="formItem">API MANUFACTURE(75987-020, 75987-021, 75987-022)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Chimie</td>
<td class="formItem"></td>
<td class="formItem">291538267</td>
<td class="formItem">API MANUFACTURE(75987-020, 75987-021, 75987-022)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2e32d121-bd9c-442f-a8d2-83672df13e7b</div>
<div>Set id: 281ab967-7565-4bef-9c0c-a646589c671e</div>
<div>Version: 6</div>
<div>Effective Time: 20140212</div>
</div>
</div> <div class="DistributorName">Horizon Pharma Inc.</div></p>
</body></html>
